TP53 and colorectal carcinoma: The majority of CRC tumors are driven by the activation of oncogenic KRAS, BRAF, and PIK3CA mutations and in-activation mutations of the tumor suppressor TP53, which have been strongly linked to metabolic reprogramming in CRC [3,4,5] and drug resistance [6].